In this podcast, Medicom’s correspondent covers 6 presentations held at the European League Against Rheumatism (EULAR 2021), held 2-5 June 2021. The topics discussed are:
- The large prospective E3N-EPIC cohort study demonstrated that exposure to passive smoking in childhood and/or adulthood is associated with an increased risk of rheumatoid arthritis (RA).
- Faecal microbiota transplantation (FMT) as an add-on therapy to methotrexate was inferior in the treatment of active peripheral psoriatic arthritis (PsA) compared with sham in the proof-of-concept, randomised, placebo-controlled FLORA trial.
- The main conclusion of a prospective, longitudinal real-world study among RA patients in the UK demonstrated that remote management provides a feasible alternative for routine outpatient follow-up.
- The risk of severe COVID-19 outcomes in patients with rheumatoid arthritis (RA) is 4 times higher for rituximab users and 2 times higher for JAK inhibitor users compared with TNF inhibitor users.
- Updates on COVID-19 vaccines in patients with rheumatic disease.
- The KEEPsAKE 2 trial showed that risankizumab leads to significantly greater improvements in signs and symptoms than placebo in patients with active psoriatic arthritis (PsA) who have shown inadequate response or intolerance to 1 or 2 biologic therapies or at least one DMARD therapy.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« ASCO 2021 Highlights Podcast Next Article
Lilly to seek accelerated FDA approval for Alzheimer’s drug this year »
« ASCO 2021 Highlights Podcast Next Article
Lilly to seek accelerated FDA approval for Alzheimer’s drug this year »
Table of Contents: EULAR 2021
Featured articles
COVID-19 Update
Rituximab or JAK inhibitors increase the risk of severe COVID-19
Updates on COVID-19 vaccines in patients with rheumatic disease
Immunomodulatory therapies for severe COVID-19: literature update
New Developments in Rheumatoid Arthritis
JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA
Remote management of RA is a feasible alternative for outpatient follow-up
TOVERA: Ultrasound is a promising biomarker of early treatment response
The risks of polypharmacy in RA
ABBV-3373: A potential new therapeutic agent for RA
JAK inhibitors and bDMARDs show comparable effectiveness
Spondyloarthritis: Progression in Therapies
SELECT-AXIS: 64-week results of upadacitinib in active ankylosing spondylitis
Guselkumab efficacious in PsA patients with inadequate response to TNF inhibition
Faecal microbiota transplantation not effective in active peripheral PsA
Risankizumab meets primary and ranked secondary endpoints in PsA
Prognostic factors for minimal disease activity in early psoriatic arthritis revealed
Imaging in Large-Vessel Vasculitis
PET/CT is a reliable measure of disease activity in LVV, but does not predict future relapses
Ultrasound is useful for disease monitoring in giant cell arteritis
Prevention in Rheumatic Diseases
Air pollution predicts decreased response to biological treatment in rheumatic diseases
Passive smoking associated with an increased risk of RA
Gene-Environment Interaction in Gout
Gene-diet and gene-weight interactions associated with the risk of gout
What Is New in Systemic Lupus Erythematosus
Intensified treatment regimen of anifrolumab for lupus nephritis is promising
Systemic lupus erythematosus: increased risk of severe infection
Juvenile Idiopathic Arthritis and Osteoarthritis
Efficacy and safety of secukinumab in juvenile idiopathic arthritis
Emerging therapies and future treatment directions in osteoarthritis
Related Articles
July 21, 2022
New treatments in osteoarthritis
September 4, 2019
What is new in osteoarthritis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com